Swedish drug discovery company Arexis AB raises SEK 63 million

Swedish drug discovery company Arexis AB raises SEK 63 million Arexis AB today announced the completion of a 63 million SEK private placement in which Industrifonden as a new investor and major owner joins current owners 3i, SEB Företagsinvest and InnovationsKapital also participating in the placement. Founded in 1999, Arexis has built a competitive drug discovery and development organization with a focus on metabolic and inflammatory diseases. Arexis bases its activities on proprietary technologies elucidating genetic components of common diseases in a uniquely time and resource efficient fashion allowing development of new drugs that are potentially more effective and selective. Through a number of collaboration and licensing agreements Arexis networks with several multinational pharmaceutical and other organizations. The new capital allows the company to reach important milestones and bring products under development closer to market. For more information please turn to: Lennart Hansson, CEO (+46 31 749 11 10 or 0706/31 00 31) or Anders Vedin (chairman of the board, phone 0708-76 15 70) Arexis AB is a drug discovery and development company, pioneering the use of genetics in highly selected disease models to pinpoint specific genes involved in multifactorial metabolic and inflammatory diseases. Founded in 1999, Arexis is dedicated to addressing unmet medical needs and delivering improved therapies based on effective and selective new drugs. The head office is in Gothenburg. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/07/01/20030701BIT00370/wkr0001.doc http://www.waymaker.net/bitonline/2003/07/01/20030701BIT00370/wkr0002.pdf